Treatment of Cerebral Sinus Venous Thrombosis Leading to Subdural Hematoma

Initial Management

The American College of Neurosurgery recommends immediate anticoagulation with either intravenous unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) as first-line therapy for cerebral sinus venous thrombosis (CSVT) leading to subdural hematoma, even in the presence of intracranial hemorrhage 1, 2
Diagnosis should be confirmed with MRI with MR venography (preferred) or CT venography if MRI is unavailable 2
Anticoagulation should be initiated immediately with either intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH) 1, 2
The presence of subdural hematoma related to CSVT is not a contraindication to anticoagulation 2
Patients should be monitored closely in a stroke unit or neurocritical care setting 2

For patients with significant mass effect from subdural hematoma, surgical evacuation may be necessary while continuing anticoagulation therapy 3
Decompressive hemicraniectomy may be considered in cases with severe mass effect 1

After initial heparin therapy, patients should be transitioned to oral anticoagulation 1, 2
The duration of anticoagulation depends on the underlying etiology, with 3-6 months for transient risk factors 1, 2, 6-12 months for unprovoked CSVT 4, and indefinite (lifelong) anticoagulation for severe thrombophilia or recurrent thrombosis 1, 2

If neurological improvement or stable, anticoagulation should be continued and transitioned to oral therapy 1
If neurological deterioration despite medical treatment, repeat neuroimaging should be performed to assess for expansion of subdural hematoma or increased mass effect 1
Surgical intervention (decompressive hemicraniectomy or hematoma evacuation) may be considered in cases of neurological deterioration 1, 3

For pediatric patients with CSVT with or without hemorrhage secondary to venous congestion, anticoagulation is suggested rather than no anticoagulation 4
Anticoagulation alone is suggested rather than thrombolysis followed by anticoagulation in pediatric patients 4
In children, anticoagulation duration is typically 6-12 months for unprovoked CSVT 4

Underlying prothrombotic conditions should be investigated as this affects treatment duration 2